Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2003 October;44(5) > The Journal of Cardiovascular Surgery 2003 October;44(5):597-603

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

ORIGINAL ARTICLES  CARDIAC SECTION


The Journal of Cardiovascular Surgery 2003 October;44(5):597-603

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Midterm experience with the Sorin Bicarbon heart valve prosthesis for rheumatic disease

Erdil N. 1, Cetin L. 2, Ates S. 2, Demirkilic U. 3, Sener E. 2, Tatar H. 3, Cakir B. 4

1 Department of Cardiovascular Surgery, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey 2 Department of Cardiovascular Surgery, Alkan Hospital, Ankara, Turkey 3 Department of Cardiovascular Surgery, Gülhane Military Hospital, Ankara, Turkey 4 Department of Public Health, Faculty of Medicine, Hacettepe University, Ankara, Turkey


Full text temporarily not available online. Contact us  


Back­ground. In ­this ­study, we ­present a ­single ­center expe­ri­ence ­with ­Bicarbon ­bileaflet ­valve in 307 ­patients ­with rheu­matic ­heart dis­ease.
­Methods. ­Between ­August 1998 and Sep­tember 2000, 307 ­patients under­went ­heart ­valve replace­ment ­using the ­Bicarbon ­bileaflet ­valve (­Sorin Bio­medica, ­Saluggia, ­Italy) ­with an ­average age of 47.19±13.21 ­years (­range 14 to 80 ­years), con­sisting of 147 ­males and 160 ­females at ­Alkan Hos­pital, Car­di­o­vas­cular Sur­gery Depart­ment. ­Aortic ­valve replace­ment (AVR) was per­formed in 77 ­patients, ­mitral ­valve replace­ment (MVR) in 156 ­patients and ­double ­valve replace­ment (DVR) in 74 ­patients.
­Results. The ­early mor­tality ­rate was 3.3% (10/307) and ­there was no ­late mor­tality. The actu­arial sur­vival ­rate, ­including hos­pital mor­tality, was 96.74±1.01% for the ­whole ­group, 96.5±1.5% for the MVR ­group, 97.4±1.8% for the AVR ­group and 97.3±1.9% for the DVR ­group at 35 ­months. One ­patient had obstruc­tive ­valve throm­bosis ­with MVR. The 35 ­months actu­arial ­freedom ­from ­valve throm­bosis was 99.58±0.4% for the ­whole ­group. ­Four ­patients ­were reop­er­ated and the ­35 ­months actu­arial ­freedom ­from reop­er­a­tion was 98.53±0.7% for the ­whole ­group, 98.65±0.9% for the MVR ­group, 96.73±02% for the DVR ­group and 100% for the AVR ­group. No ­instances of per­i­val­vular ­leak, hemol­ysis, endo­car­ditis or embo­lism ­were ­observed ­during the ­entire ­follow-up ­period. ­Mean ­follow-up dura­tion was 16.5±7.9 ­months (­ranged 4 to 35 ­months).
Con­clu­sions. We ­have pre­sented our mid-­term ­results ­with the ­Sorin ­Bicarbon ­bileaflet ­valve in ­patients ­with rheu­matic ­heart dis­ease, ­which pro­vided ­good clin­ical per­for­mance com­bined ­with metic­u­lous ­patient ­care and ­advanced sur­gical tech­niques.

top of page

Publication History

Cite this article as

Corresponding author e-mail